Short Bowel Syndrome
Conditions
Keywords
Short bowel syndrome
Brief summary
The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.
Detailed description
The only effective (to some extend drug) in short bowel syndrome is Glucacone-like peptide 4. Its price is, however, to high to really change the treatment strategy for intestinal failure. The Dipeptidyl peptidase-4 inhibitor, which a drug which is commonly used in the treatment of diabetes mellitus type II, should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.
Interventions
Sponsors
Stanley Dudrick's Memorial Hospital
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months * stable metabolic status * benign disease
Exclusion criteria
* HPN \< 12 months * metabolically unstable * cancer as the reason for intestinal failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of intestinal absorption | 12 months | the use of DPP-4 inhibitor results in the better intestinal absorption |
Countries
Poland
Outcome results
None listed